Bristol Myers licenses for Evotec molecule for $20M; FDA approves Impel's migraine nasal spray Trudhesa
Bristol Myers Squibb has exercised its option with Evotec for EVT8683, a small molecule created by the German biotech to target a specific “cellular stress response.”
The companies have obtained clearance to start human trials, close to 4.5 years after initiating a partnership.
According to an Evotec statement, “the programme targets a key cellular stress response mechanism which has the potential to deliver disease-modifying treatments for several devastating neurodegenerative diseases.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.